Global Human Growth Hormone Treatment and Drugs Market to Reach USD 5.26 Billion by 2033

The global human growth hormone treatment and drugs market, valued at USD 3.67 Billion in 2023, is projected to grow steadily at a Compound Annual Growth Rate (CAGR) of 3.7% from 2023 to 2033, reaching approximately USD 5.26 Billion by the end of the forecast period.

Human growth hormone (hGH), also known as Somatotropin, is pivotal in human development, influencing cell regeneration, reproduction, and growth stimulation. The market’s growth is driven by increasing incidences of conditions such as Prader-Willi syndrome, Turner syndrome, and idiopathic short stature (ISS), which are associated with hGH deficiency. These conditions can lead to delayed puberty and shorter-than-average height due to inadequate synthesis by the pituitary gland.

Get your Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-14401

While hGH serves as a vital medication for these conditions, it has unfortunately seen misuse in the realms of bodybuilding, sports, and among older adults seeking anti-aging solutions. It’s essential to note that the USFDA has not approved hGH for anti-aging or performance-enhancing purposes due to its classification as a prohibited substance.

However, the demand for medication growth hormones continues to rise, addressing the growing prevalence of these conditions among both young and elderly populations worldwide. The availability of human growth hormone medications in the market is contributing to increased awareness of their health benefits, subsequently driving revenue growth for manufacturing companies.

As we move forward, it’s crucial for stakeholders across the healthcare spectrum to ensure the responsible and ethical use of human growth hormone, emphasizing its intended medical purposes while discouraging its misuse for non-approved applications.

Key Takeaways: Human Growth Hormone Treatment and Drugs Market (2023-2033)

• The global Human Growth Hormone Treatment and Drugs Market is expected to reach a value of around USD 5.26 billion by 2033, reflecting a steady growth at a Compound Annual Growth Rate (CAGR) of 3.7% from 2023 to 2033.
• Growth Drivers:
  • Increasing geriatric population with growth in hormone replacement therapies.
  • Rising awareness about growth hormone deficiencies and their treatment options.
  • Growing investments in research and development (R&D) for novel Human Growth Hormone (HGH) therapies.
  • Expanding government initiatives supporting hormone therapies.
• Market Potential: A robust product pipeline, diversification of treatment options, and increasing focus on patient well-being are expected to propel market growth further.

 “A healthy product portfolio and extensive Market research investments for the emergence of future growth hormone treatments are projected to propel the sales of human growth hormone treatment & drugs.”

Request for Customization: https://www.futuremarketinsights.com/customization-available/rep-gb-14401

Competitive Landscape:

Advancements in the development of more efficient chemical formulations are poised to boost the demand for adult human growth hormone injections, benefiting market participants. Leading companies in this sector are actively pursuing mergers and acquisitions to extend their market presence and ramp up the production of human growth hormone injections.

• In February 2022, Pfizer Inc. and OPKO Health, Inc. introduced NGENLA, a once-weekly injection of a long-acting recombinant human growth hormone authorized by the European Commission. This injection is indicated for treating inadequate growth hormone secretion from infancy up to adolescence.
• Additionally, in 2021, the US Food and Drug Administration (FDA) approved Eli Lilly’s product Verzenio (abemaciclib), a CDK4/6 inhibitor for high-risk early breast cancer with HR+ HER2- status.

Key Companies Profiled:

• Ankebio Co. Ltd.
• Eli Lilly and Company
• Emd Serono
• Ferring Pharmaceuticals
• Genentech Inc.
• Gene Science Pharmaceutical Co. Ltd.
• Ipsen, LG Life Sciences
• Merck KGaA
• Novo Nordisk
• Ascendis Pharma
• Pfizer Inc.

Key Market Segments Covered in Human Growth Hormone Treatment and Drugs Market Industry:

By Route of Administration:

• Subcutaneous
• Intramuscular
• Intravenous
• Oral

By Application:

• Growth Hormone Deficiency
• Turner Syndrome
• Idiopathic Short Stature (ISS)
• Prader-Willi Syndrome (PWS)
• Other Applications

By Distribution Channel:

• Hospital Pharmacy
• Specialty Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• The Middle East and Africa (MEA)

A Full Report on Market: https://www.futuremarketinsights.com/checkout/14401

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube